TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26566161
Drug: Etravirine 5.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etravirine 5.2 mg/kg twice daily with a background regimen (boosted protease inhibitor plus nucleoside/nucleotide reverse transcriptase inhibitors, optional enfuvirtide/raltegravir)
Study: 26566161
Drug: Etravirine 5.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etravirine 5.2 mg/kg twice daily
Study: 26566446
Drug: Bollywood dance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bollywood dance classes (1 hour, twice per week for 8 weeks)
Study: 26566914
Drug: Genetic testing
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetic testing for the m.3243A>G MELAS mutation
Study: 26567113
Drug: [(64)Cu]DOTA-patritumab (9.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: [(64)Cu]DOTA-patritumab (9.0 mg/kg)
Study: 26567860
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose infusion (IVGI)
Study: 26568466
Drug: 3-day treatment
Normalized name: Gyne-Lotrimin 2% 3-Day Treatment Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day treatment (15 mg/m² every 8 hours for three consecutive days/cycle/6 weeks)
Study: 26568466
Drug: 5-day treatment
Normalized name: 30 day Acne Treatment Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day treatment (20 mg/m² once daily on days 1-5/cycle/4 weeks)
Study: 26568466
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (3-day and 5-day)
Study: 26571268
Drug: Bee venom
Normalized name: Bee venom
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bee venom treatment (subchronic)
Study: 26571268
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of bee venom
Study: 26571268
Drug: Apamin (blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apamin (blocker of SK channels)
Study: 26571268
Drug: CyPPA (positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CyPPA (positive modulator of SK channels)
Study: 26571268
Drug: Control (neuroleptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (neuroleptic treatment and 6-hydroxydopamine injection)
Study: 26571311
Drug: rSm14/GLA-SE vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: rSm14/GLA-SE vaccine (50 μg rSm14 with 10 μg GLA-SE, intramuscularly, three doses with 30-day intervals)
Study: 26573078
Drug: DPYD*2A genotype-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPYD*2A genotype-guided dosing (initial dose reduction of ≥ 50%)
Study: 26573078
Drug: DPYD*2A genotype-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPYD*2A genotype-guided dosing
Study: 26573686
Drug: Other analgesic
Normalized name: OTHER ANALGESICS AND ANTIPYRETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other analgesic drugs
Study: 26574583
Drug: Diesel exhaust
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diesel exhaust (300 µg PM(2.5)/m(3))
Study: 26575422
Drug: Intra-tumor injection
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-tumor injection of AvidinOX with low dose bCet
Study: 26576059
Drug: Hydroxyurea (15-35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (15-35 mg/kg/day)
Study: 26577132
Drug: Smart infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Smart infusion pumps (SIP)
Study: 26577301
Drug: PI combined
Normalized name: PI-103
DrugBank: PI-103 (DB17046)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PI combined with external beam radiation therapy (PI + EBRT)
Study: 26578722
Drug: Everolimus (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (30 mg weekly) with Carboplatin (area under the curve 6) and Paclitaxel (200 mg/m²) every 3 weeks
Study: 26578731
Drug: Hepatic artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic artery infusion (HAI) with triplet chemotherapy (irinotecan 180 mg/m², oxaliplatin 85 mg/m², 5-fluorouracil 2800 mg/m²) and systemic cetuximab (500 mg/m²) every 14 days.
Study: 26578731
Drug: Hepatic artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic artery infusion (HAI) with triplet chemotherapy and systemic cetuximab.
Study: 26581135
Drug: 60 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 Gy intensity modulated radiation therapy with concurrent weekly intravenous cisplatinum (30 mg/m(2))
Study: 26581137
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) with a prescribed dose of 48 Gy at the isocenter in 4 fractions
Study: 26582805
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) insulin therapy
Study: 26582853
Drug: Lidocaine 1%
Normalized name: LIDOCAINE 1% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1% ACB with 20 ml
Study: 26582853
Drug: Lidocaine 1%
Normalized name: LIDOCAINE 1% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1% ACB with varying volumes (5 ml, 10 ml, 15 ml, 20 ml)
Study: 26583301
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion of relaxin over 48 hours
Study: 26584601
Drug: Endoscopic remission
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endoscopic remission defined as absence of white exudates, moderate or severe rings, strictures, or combination of furrows and edema
Study: 26585432
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for 21 days
Study: 26588924
Drug: ibrutinib 420
Normalized name: ibrutinib 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibrutinib 420 mg
Study: 26588924
Drug: ibrutinib 560
Normalized name: ibrutinib 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibrutinib 560 mg
Study: 26588924
Drug: ibrutinib 140
Normalized name: ibrutinib 140 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibrutinib 140 mg and 280 mg (single-dose phase)
Study: 26588924
Drug: ibrutinib 420
Normalized name: ibrutinib 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibrutinib 420 mg (multiple-dose phase)
Study: 26589752
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of allogeneic mesenchymal stromal cells (MSCs) at a median dose of 2.7 × 10(6) cells/kg/infusion, range 1.3-4.5, given weekly for 2 to 5 weeks, in addition to standard rabbit ATG and cyclosporine.
Study: 26589963
Drug: Canakinumab treatment
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab treatment in SJIA patients
Study: 26589963
Drug: Active AOSD
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active AOSD prior to canakinumab treatment
Study: 26590174
Drug: Intravenous abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous abatacept (∼10 mg/kg) plus MTX for 24 weeks
Study: 26595450
Drug: 3-drug regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-drug regimen (ledipasvir, sofosbuvir, GS-9451) for 4 weeks
Study: 26595450
Drug: 4-drug regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4-drug regimen (ledipasvir, sofosbuvir, GS-9451, GS-9669) for 4 weeks
Study: 26597180
Drug: Dasotraline 4
Normalized name: Dasotraline
DrugBank: Dasotraline (DB12305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasotraline 4 or 8 mg/day
Study: 26597180
Drug: Dasotraline (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasotraline (various doses from 0.2 to 36 mg)
Study: 26597443
Drug: Cetuximab in
Normalized name: cetuximab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab in combination with 5-fluorouracil (5FU) and mitomycin C (MMC) during chemoradiotherapy (CRT)
Study: 26597443
Drug: 5-fluorouracil (5FU)
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5FU) 800 mg/m(2) on RT days 1-4 and 29-32 and mitomycin C (MMC) 8 mg/m(2) on days 1 and 29
Study: 26597443
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of cetuximab
Study: 26597653
Drug: Topical mosquito
Normalized name: mosquito allergenic extract
DrugBank: Aedes taeniorhynchus (DB10691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mosquito repellent distribution scheme (2-weekly bottle exchange programme)
Study: 26597937
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment provided by family physician.
Study: 26598545
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HER2-PET/CT and FDG-PET/CT
Study: 26602014
Drug: Toremifene 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene 180 mg daily
Study: 26602164
Drug: Plerixafor (CXCR4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plerixafor (CXCR4 antagonist)
Study: 26603536
Drug: lanreotide Autogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: lanreotide Autogel 120 mg every 4 weeks
Study: 26603828
Drug: Duloxetine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (30 mg/day for 7 days, then 60 mg/day for 4 weeks)
Study: 26606867
Drug: self-complementary AAV
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: self-complementary AAV [scAAV]2(Y444,500,730F)-P1ND4v2 at low dose (5 × 10(9) vg)
Study: 26606867
Drug: self-complementary AAV
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: self-complementary AAV [scAAV]2(Y444,500,730F)-P1ND4v2 at medium dose (2.46 × 10(10) vg)
Study: 26607424
Drug: EMA-approved dose
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMA-approved dose
Study: 26607424
Drug: FDA-approved dose
Normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDA-approved dose
Study: 26607977
Drug: Compliance with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compliance with dose constraints for target volumes
Study: 26607977
Drug: Compliance with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compliance with dose constraints for OAR
Study: 26608460
Drug: Lateral flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral flow test (LFT) with G12 monoclonal antibody for gluten immunogenic peptides (GIP)
Study: 26608976
Drug: OROS-MPH (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS-MPH (18 mg, 36 mg, or 54 mg)
Study: 26610172
Drug: Group drumming
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group drumming intervention, details on dosage and duration not available
Study: 26612014
Drug: ledipasvir/sofosbuvir (LDV/SOF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ledipasvir/sofosbuvir (LDV/SOF) (90 mg/400 mg) daily for 12 weeks
Study: 26612014
Drug: ledipasvir/sofosbuvir (LDV/SOF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ledipasvir/sofosbuvir (LDV/SOF) + GS-9451 (80 mg/day) daily for 6 weeks
Study: 26612014
Drug: ledipasvir/sofosbuvir (LDV/SOF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ledipasvir/sofosbuvir (LDV/SOF) + GS-9669 (500 mg twice daily) for 6 weeks
Study: 26612014
Drug: Recent drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recent drug use
Study: 26612321
Drug: Neoadjuvant concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant concurrent chemoradiotherapy with hematopoietical bone marrow sparing
Study: 26612701
Drug: PPI (Proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI (Proton Pump Inhibitors)
Study: 26612701
Drug: H2 RA
Normalized name: RAS
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: H2 RA (H2-receptor antagonists)
Study: 26612870
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg posaconazole (as tablets) once daily (twice daily on day 1) for up to 28 days
Study: 26612873
Drug: Intravesicular cidofovir
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravesicular cidofovir (2.5-5 mg/kg in 50-100 mL of normal saline) administered via transurethral catheter after oral probenecid (2 g) for up to 2 h of dwell time.
Study: 26612979
Drug: Dabigatran 220
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 220 mg once daily after switching from enoxaparin 40 mg for thromboprophylaxis
Study: 26612979
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg for thromboprophylaxis
Study: 26614268
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg once daily for 4 weeks
Study: 26614966
Drug: Disulfiram 500
Normalized name: disulfiram 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram 500 mg
Study: 26614966
Drug: Disulfiram 1000
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram 1000 mg
Study: 26614966
Drug: Disulfiram 2000
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram 2000 mg
Study: 26615061
Drug: Hydroxyurea treatment
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea treatment with a pharmacokinetic-guided dosing strategy, initial dose of 20 mg/kg oral dose.
Study: 26615061
Drug: Pharmacokinetic-guided dosing
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetic-guided dosing strategy
Study: 26616030
Drug: Guideline-directed medical
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-directed medical therapy (GDMT) plus revascularization (percutaneous coronary intervention or coronary artery bypass graft surgery)
Study: 26618098
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma therapy (2 units)
Study: 26619773
Drug: Clozapine treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine treatment, dosage and duration not specified
Study: 26619834
Drug: Vorinostat 400
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat 400 mg plus bortezomib 1.3 mg/m(2)
Study: 26621580
Drug: Quercetin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (up to 5 g daily)
Study: 26622643
Drug: Belinostat in
Normalized name: belinostat Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide
Study: 26625449
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (both doses)
Study: 26627079
Drug: Volasertib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volasertib (300 mg)
Study: 26627079
Drug: Volasertib (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volasertib (350 mg)
Study: 26627079
Drug: Volasertib (200-350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volasertib (200-350 mg)
Study: 26627107
Drug: E/C/F/TAF (elvitegravir
Approvals — FDA: no, EMA: no, PMDA: no
Description: E/C/F/TAF (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, TAF 10 mg)
Study: 26628614
Drug: ACP-501 (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACP-501 (recombinant human LCAT) at 0.9 mg/kg
Study: 26628614
Drug: ACP-501 (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACP-501 (recombinant human LCAT) at 3.0 mg/kg
Study: 26628614
Drug: ACP-501 (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACP-501 (recombinant human LCAT) at 9.0 mg/kg
Study: 26628614
Drug: ACP-501 (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACP-501 (recombinant human LCAT) at 13.5 mg/kg
Study: 26628838
Drug: EVL plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVL plus somatostatin (250 mcg/hr)
Study: 26630396
Drug: Pulmonary vasodilator
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary vasodilator therapy (phosphodiesterase-5 inhibitors, 88% at entry, 87% after 1 year)
Study: 26630396
Drug: Pulmonary vasodilator
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary vasodilator therapy (phosphodiesterase-5 inhibitors)
Study: 26631428
Drug: Lurasidone 20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 20, 40, 80, 120, and 160 mg/d
Study: 26631428
Drug: Lurasidone doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone doses <120 mg/d
Study: 26631428
Drug: Lurasidone (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone (multiple doses)
Study: 26631691
Drug: Oral moisturizing
Normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral moisturizing jelly (OMJ) used for 2 weeks
Study: 26631691
Drug: Oral moisturizing
Normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral moisturizing jelly (OMJ) used for 1 month
Study: 26632544
Drug: other treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: other treatments
Study: 26632544
Drug: antiviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: antiviral treatment
Study: 26632544
Drug: nutritional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: nutritional treatment
Study: 26632545
Drug: Immunotherapy strategies
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy strategies including vaccines, adaptive therapy, immune checkpoint blockades, and cytokines.
Study: 26632880
Drug: Chemotherapy-induced pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy-induced pain (CHIP)
Study: 26635965
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention followed by standard fertility treatments after 6 months if no conception has been achieved
Study: 26635965
Drug: Standard fertility
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fertility treatments only
Study: 26637464
Drug: Artemisinin combination
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin combination therapies (ACTs) during early pregnancy
Study: 26637464
Drug: Pregnant women
Normalized name: Hydroxyprogesterone Caproate 250mg/1mL Solution for injection [For Non-pregnant Women]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnant women treated for malaria but exposed to other antimalarials
Study: 26639348
Drug: Venetoclax (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (150 to 1200 mg per day in dose-escalation phase; up to 400 mg per day in expansion cohort)
Study: 26639348
Drug: Venetoclax (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (400 mg per day)
Study: 26639404
Drug: Vector insertion
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vector insertion sites (VIS) in iC9-T cells pre- and post-CID administration.
Study: 26640039
Drug: Ibrutinib (560
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (560 mg daily) combined with Rituximab (375 mg/m2 IV once per week for 4 weeks, then on day 1 of cycles 3-8, and thereafter once every other cycle up to 2 years)
Study: 26640780
Drug: Anti-CEA × anti-histamine-succinyl-glycine (HSG)-humanized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CEA × anti-histamine-succinyl-glycine (HSG)-humanized trivalent bispecific antibody (TF2) and IMP288 bivalent HSG peptide
Study: 26640780
Drug: TF2 pharmacokinetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: TF2 pharmacokinetics (PK)
Study: 26640780
Drug: (111)In- and
Normalized name: metformin and ertugliflozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: (111)In- and (177)Lu-IMP288 pharmacokinetics (PK)
Study: 26641137
Drug: Acalabrutinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acalabrutinib (100 to 400 mg once daily in phase 1, 100 mg twice daily in phase 2)
Study: 26643737
Drug: Successful drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful drug-eluting stent implantation
Study: 26645405
Drug: Carboplatin administered
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin administered intravenously for 60 min after blood-brain barrier disruption using an implantable ultrasound device.
Study: 26645894
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment in early life
Study: 26646829
Drug: Ultra-low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low dose IL-2
Study: 26646829
Drug: Initial learning
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial learning phase with six different doses and frequencies of IL-2
Study: 26647281
Drug: DC-based vaccine
Normalized name: covid-19, RNA-based vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DC-based vaccine loaded with autologous HIV-1-infected apoptotic cells
Study: 26648747
Drug: Olaparib maintenance
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib maintenance therapy (placebo-controlled)
Study: 26649075
Drug: MBP-NC (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBP-NC (200 mg red yeast rice extract, 500 mg berberine, 10 mg policosanols)
Study: 26649337
Drug: Contrast enhanced
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast enhanced ultrasound (CEUS) with 2.4 ml SonoVue
Study: 26649807
Drug: Cetuximab combined
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab combined with docetaxel (weekly cetuximab: first infusion 400 mg/m², then 250 mg/m²; docetaxel: 100 mg/m² every 3 weeks)